1. Home
  2. ALT vs AACB Comparison

ALT vs AACB Comparison

Compare ALT & AACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • AACB
  • Stock Information
  • Founded
  • ALT 1997
  • AACB 2024
  • Country
  • ALT United States
  • AACB United States
  • Employees
  • ALT N/A
  • AACB N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • AACB
  • Sector
  • ALT Health Care
  • AACB
  • Exchange
  • ALT Nasdaq
  • AACB Nasdaq
  • Market Cap
  • ALT 348.6M
  • AACB 283.7M
  • IPO Year
  • ALT N/A
  • AACB 2025
  • Fundamental
  • Price
  • ALT $4.05
  • AACB $10.23
  • Analyst Decision
  • ALT Strong Buy
  • AACB
  • Analyst Count
  • ALT 7
  • AACB 0
  • Target Price
  • ALT $16.50
  • AACB N/A
  • AVG Volume (30 Days)
  • ALT 2.8M
  • AACB 24.2K
  • Earning Date
  • ALT 11-06-2025
  • AACB 01-01-0001
  • Dividend Yield
  • ALT N/A
  • AACB N/A
  • EPS Growth
  • ALT N/A
  • AACB N/A
  • EPS
  • ALT N/A
  • AACB N/A
  • Revenue
  • ALT $20,000.00
  • AACB N/A
  • Revenue This Year
  • ALT N/A
  • AACB N/A
  • Revenue Next Year
  • ALT N/A
  • AACB N/A
  • P/E Ratio
  • ALT N/A
  • AACB N/A
  • Revenue Growth
  • ALT N/A
  • AACB N/A
  • 52 Week Low
  • ALT $2.90
  • AACB $9.85
  • 52 Week High
  • ALT $11.16
  • AACB $10.27
  • Technical
  • Relative Strength Index (RSI)
  • ALT 54.55
  • AACB N/A
  • Support Level
  • ALT $3.93
  • AACB N/A
  • Resistance Level
  • ALT $4.25
  • AACB N/A
  • Average True Range (ATR)
  • ALT 0.18
  • AACB 0.00
  • MACD
  • ALT 0.00
  • AACB 0.00
  • Stochastic Oscillator
  • ALT 56.99
  • AACB 0.00

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About AACB Artius II Acquisition Inc. Class A Ordinary Shares

Artius II Acquisition Inc is a blank check company.

Share on Social Networks: